Brief Article
Copyright ©2010 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 14, 2010; 16(46): 5845-5851
Published online Dec 14, 2010. doi: 10.3748/wjg.v16.i46.5845
Table 1 Patient characteristics
Age (yr): median (range)25 (19-44)
Disease duration, years median (range)5.1 (0.4-27)
No. of patients%
Disease location
Ileum213
Colon427
Ileocolon960
Disease type
Inflammatory747
Stricturing533
Inflammatory + perianal320
Prior anti-TNF-therapy427
Prior bowel operation427
Smokers747
Baseline concomitant medication
Azathioprine/6-mercaptopurine1067
Methotrexate213
Corticosteroids1067
Mesalamine or sulphasalazine1387
Week 12 concomitant medication
Azathioprine/6-mercaptopurine1387
Methotrexate213
Corticosteroids16.7
Mesalamine or sulphasalazine1173
CDAI at baseline, median (range)158 (49-605)
CDAI at week 12, median (range)66 (24-202)
Table 2 The effect of Crohn's disease patient serum withdrawn before anti-tumor necrosis factor-α therapy on forkhead transcription factor 3, glucocorticoid-induced tumour necrosis factor receptor and interferon γ specific mRNA expression (relative units) and interferon γ, interleukin-5 and interleukin-17 secretion (pg/mL) from peripheral blood mononuclear cells obtained from healthy volunteers (target cells)
RT-qPCR
ELISA
Patient No.FOXP3FOXP3 PHAGITRGITR PHAIFNγIFNγ PHAIFNγ PHAIL-5 PHAIL-17 PHA
14.953.810.865.01.811.71580.08.40.0
28.265.418.7175.93.830.537 400.080.519.4
312.9127.730.8452.911.6128.9172 000.0187.0239.0
49.2153.732.5399.25.052.097 600.0154.0265.0
510.068.422.8183.28.222.638 100.081.5118.0
64.04.68.955.21.310.40.00.542.7
711.536.722.4107.06.119.31460.08.520.9
87.997.017.93171.05.826.20.06.582.0
94.640.79.366.63.04.50.01.00.0
106.468.315.8145.84.215.828.84.10.0
117.496.917.0251.43.436.1173.07.40.0
126.986.415.1217.44.336.2223 000.0144.0638.0
135.232.714.183.03.85.311 600.03.3341.0
143.881.612.7180.72.913.51660.00.5181.0
155.431.29.954.43.63.316 100.05.5310.0